Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Bijal D ShahRyan D CassadayJae H ParkRoch HouotOlalekan O OluwoleAaron C LoganNicolas BoisselThibaut LeguayMichael R BishopMax S ToppDimitrios TzachanisKristen M O'DwyerMartha L ArellanoYi LinMaria R BaerGary J SchillerMarion SubkleweMehrdad AbediMonique C MinnemaWilliam G WierdaDaniel J DeAngeloPatrick J StiffDeepa JeyakumarDaqin MaoSabina AdhikaryLang ZhouPetra C SchuberthRita Damico KhalidArmin GhobadiaPublished in: Journal for immunotherapy of cancer (2023)
In ZUMA-3, adults with R/R B-ALL benefited from brexu-cel, regardless of prior therapies and subsequent alloSCT status, though survival appeared better in patients without certain prior therapies and in earlier lines of therapy. Additional studies are needed to determine the impact prior therapies and subsequent alloSCT have on outcomes of patients who receive brexu-cel.